frequently on a case-by-case basis, often influenced by previous personal experience. They highlighted the increasing concerns from the participating hospitals’ microbiology departments over the use of quinolones due to the risks of selecting drug resistant organisms and Clostridium difficile (C. difficile) associated diarrhoea. Rifaximin is licensed in use for HE but may have beneficial role in SBP prevention without the high risk of drug resistance, however high costs remains a barrier to its use.

SBP continues to be a significant problem in the management of patients with decompensated liver failure. The Results from these centres demonstrate an evident lack of clarity over the optimum strategy for primary prophylaxis throughout the United Kingdom and hence the need for further high quality research to provide clear guidelines.

REFERENCES

PWE-088 EVALUATION OF DRUG-INDUCED SERIOUS HEPATOTOXICITY (eDISH) ASSESSMENT IN OBETICHOLIC ACID-TREATED PATIENTS WITH NASH


Introduction: Evaluation of drug-induced serious hepatotoxicity (eDISH) is a tool used to assess and identify potential cases of drug-induced liver injury (Senior J. Drug Safety, 2014;(37): Suppl 1:S9–S17). eDISH was used to evaluate obeticholic acid (OCA) and placebo profiles in 2 double-blind, placebo-controlled studies in patients with NASH. FLINT was a 72 week study, which demonstrated statistically significant improvements in hepatic ballooning, steatosis, lobular inflammation, and fibrosis in patients treated with OCA compared to placebo. CONTROL was a 16 week study, which showed that the addition of low-dose atorvastatin reversed OCA-associated changes in LDL-C. The objective of this analysis was to use eDISH to determine if patients with NASH treated with OCA showed increased markers of liver injury or whole liver dysfunction.

Methods: eDISH Methodology was applied to 278 patients treated with placebo (n=140) or 25 mg OCA (n=138) from FLINT and 84 patients treated with placebo (n=21), 5 mg OCA (n=20), 10 mg OCA (n=21), or 25 mg OCA (n=22) from CONTROL. Individual peak of ALT and total bilirubin values during the double-blind treatment phase were plotted as log10 values of multiples of elevations above the upper limit of the normal (xULN).

Results: Overall, no OCA-treated patients were in the Hy’s law quadrant (>3 x ULN for ALT and >2 x ULN for total bilirubin) compared with 1 placebo-treated patient in FLINT. The proportion of patients with peak ALT and total bilirubin values in the lower left quadrant (representing normal or near normal range) was higher in OCA-treated patients compared with placebo (FLINT: 91% OCA vs 84% placebo; CONTROL: 91% OCA vs 86% placebo). 8% of OCA-treated patients from both FLINT and CONTROL presented in the Temple’s corollary quadrant (>3 x ULN for ALT and <2 x ULN for total bilirubin) vs 14% (in both studies) for the placebo-treated patients. Across both studies (n=362), 4 patients were in the cholestasis quadrant (>2 x ULN total bilirubin and <3 x ULN for ALT); 1 placebo-treated patient and 3 OCA-treated patients, including 1 patient with Gilbert’s syndrome.

Conclusions: In these 2 placebo-controlled, double-blind NASH studies, the eDISH analysis showed no trend for liver injury with OCA at doses up to and including 25 mg.

Evaluation of Drug-Induced Serious Hepatotoxicity

PWE-089 ROUTINELY COLLECTED HEALTH DATA TO STUDY THE SURVEILLANCE FOR COMPLICATIONS OF ADVANCED CHRONIC LIVER DISEASE


Introduction: Screening for oesophageal varices and surveillance for hepatocellular carcinoma (HCC) are recommended to improve outcomes for patients with cirrhosis. The adherence with the recommendations is unknown. Disease registries have improved care for patients with heart disease and inflammatory bowel disease. To date there is no registry for patients with cirrhosis. The aim of this study was to determine if information routinely collected in electronic health records (EHR) can be used to evaluate rates of surveillance testing in patients with advanced chronic liver disease (ACLD).

Method: Transient elastography (TE) data was collected from St James’s University Hospital in Leeds between 2012 and 2017. Inclusion criteria were a valid liver stiffness measurement (LSM) ≥10 kPa to identify patients likely to have ACLD. Disease and procedural coding information sent to NHS Digital and held in EHR was used to determine the number of patients who underwent screening or surveillance. For the purposes of the analysis variceal screening was defined as a gastroscopy within 12 months of TE and HCC surveillance was at least one abdominal ultrasound scan (US) with a mean interval between scans of 2–9 months during the follow-up period. Patients were stratified based on LSM into two groups: ≥10–15 kPa or >15 kPa. Validation of the coding information was done in a subset of patients where the full clinical record was reviewed to determine the accuracy of the coded EHR data.

Results: 1046 patients underwent TE (Median LSM 16.2 kPa; 489 ≥10–15 kPa, 557 >15 kPa). Median follow-up interval was 36 months. Considering only those patients with LSM >15 kPa, 166 (30%) patients had a gastroscopy within 12 months. Of these, 44/166 (27%) patients had a primary diagnosis code for oesophageal varices. Using the primary diagnosis code to determine the presence or absence of varices was validated in 100 patients and showed good performance characteristics: sensitivity 0.91; specificity 0.88. Regarding HCC surveillance, 647/1046 patients (62%) had undergone at least one US. 45/489 patients (9.2%) with a...
LSM ≥10–15 kPa and 124/557 patients (22.3%) with a LSM >15 kPa were identified as having regular surveillance for HCC.

Conclusions This study shows that information routinely collected in EHR can be used to evaluate screening and surveillance strategies in patients with cirrhosis. Only a minority of patients had undergone the recommended interventions within the definitions of this study. This highlights the potential for a cirrhosis registry to impact on patient care and to improve outcomes for patients with cirrhosis.

**PWE-090** WEST MIDLANDS MULTI-CENTRE TRAINEE-LED AUDIT IN THE ASSESSMENT, MANAGEMENT AND PROPHYLAXIS OF SPONTANEOUS BACTERIAL PERITONITIS

Keith Siau*, B Hicken, A McCulloch, M Hasborne, T Gupta, B Polewiczowski, T Troth, M McFarlane, E Miodalk, A Thakor, Z Rehan, L O’Flynn, Monika Walidk, (West Midlands Research in Gastroenterology, UK

Introduction Spontaneous bacterial peritonitis (SBP) is a common but potentially fatal complication in patients with cirrhosis and ascites. In the first audit performed by West Midlands Research in Gastroenterology (WMRIG) trainees, we aimed to assess practice of assessment, management and primary and secondary prophylaxis of SBP according to national standards, in addition to the feasibility of regional project delivery.

Methods This trainee-led, retrospective, multi-centre study identified patients admitted with cirrhosis and ascites between Sep-Dec 2016. Outcomes of SBP and mortality were retrospectively followed-up for up to 1 year (median 8 months). Practice was audited against EASL, BSG and NICE standards. Heterogeneity between sites was assessed with chi² and time-to-event analyses undertaken using Kaplan-Meier plots.

Results Trainees across 8 West Midlands hospitals identified 227 patients (mean age 58, SD 13; 65% male) with 282 admissions. Cirrhosis was attributed to alcohol (79%), NAFLD (10%), autoimmune (4%) and viral (3%), and was graded Child-Pugh B in 48% and C in 49%. 18% were elective admissions and 7% had a previous history of SBP. Ascitic aspirates were performed in 83% (range: 60%–92%, p=0.019), in <24 hours in 64% (range: 49%–85%, p=NS), and cultures sent in 55% (range: 11%–86%, p<0.001). 16.8% of aspirates met criteria for SBP: antibiotics were commenced in 92% (p<0.001), Day 1 albumin in 64% (p=NS), Day 3 albumin in 40% (p=NS), and secondary prophylaxis in 44% (p=NS). Repeat aspirate to ensure SBP resolution was performed in 33% (range: 0%–52%, p=NS). In patients without SBP, ascitic protein was measured in 46% (not available in 3 Trusts). 32 (67%) met criteria for primary prophylaxis (protein≤15 g/L); which was commenced in 4 (13%), range 0%–100%, p=NS. Mortality occurred in 51%. SBP was associated with lower median survival (79 days vs. non-SBP: 190 days, p=0.045) [figure 1]. Emergency admission (HR 8.4, p=0.039), older age (HR 1.03 per increase, p=0.017) and ascitic protein ≤15 g/L (HR 2.27, p=0.042) were multivariate predictors of reduced survival. SBP occurred after discharge in 8 patients (4%) after a median interval of 32 days.

Conclusions Our pilot study has been successful in highlighting deficiencies and variations in the assessment, management and prophylaxis of SBP. These Results will inform and prioritise future regional quality improvement strategies to improve outcomes in patients with advanced chronic liver disease.

**PWE-091** L-ORNITHINE L-ASPARTATE IN MINIMAL HEPATIC ENCEPHALOPATHY: POSSIBLE EFFECTS ON THE BRAIN-MUSCLE AXIS?


Introduction L-Ornithine L-Aspartate (LOLA) is an ammonia-lowering agent for treatment of hepatic encephalopathy (HE); it may reduce sarcopenia. We investigated 12 weeks of oral LOLA in patients with compensated cirrhosis and minimal HE (MHE).

Methods Consecutive patients were pre-screened with paper-and-pencil-based psychometric testing (PHES test) and included if performance was impaired to a level of −4 or worse. 34 English-speakers were included; 12 randomised to 12 weeks oral LOLA 6 g tds, 22 randomised to identical-looking placebo. At baseline, 4 and 12 weeks, subjects had PHES, a computerised battery: Cogstate™ and SF-36 health questionnaires. Markers of muscle function were recorded: handgrip strength, skin fold thickness, and 6-minute-walk-test. Subjects had cerebral T₁ and T₂ MRI, functional MRI (fMRI) with motor/cognitive tasks/resting state studies; and 1H MRS. LC Model software was used for metabolite identification.

Results On SF-36, 57% on LOLA reported better energy levels than placebo 0.04% (P-value<0.001). Better concentration was reported by 21% in treatment arm vs none in placebo group (p=0.05). 28% reported improved memory in treatment group vs 0.04% with placebo. Sleep improvements were reported by 35% in treatment arm vs 0.9% on placebo (p=0.05). In both groups, changes in total PHES score and Cogstate™ were non-significant. PHES test sub-analysis of the Digit-Symbol showed significant improvement in performance in LOLA-treated group (p=0.05). Biceps skinfold thickness showed a mean gain of 1.5 mm in the LOLA group with mean loss of 1.0 mm (p=0.05) in placebo. No differences were found in other skinfolds, hand-grip or 6-minute-walk-test. On T₁ cerebral MRI, significant volume reduction was seen in left lateral ventricle, right globus pallidus and mid-anterior corpus callosum (ACC). fMRI tasks did not vary between groups. ¹H MRS of ACC showed significant changes in glutamate concentration (p=0.03), after LOLA.